Atlas Venture | Activity | F4Atlas Venture Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Essay
Atlas analysis on life sciences as a segment of broader venture funding landscape amid AI/ML funding concentration.
Stay Humble: Life Sciences as a Small Slice of an Increasingly Big Venture Pie
Portfolio company Kailera Therapeutics completed IPO raising $625M, one of biotech's biggest-ever offerings.
Milestone
Portfolio company Obsidian merged with Galera Therapeutics and secured $350M concurrent private placement to advance TIL cell therapy programs.
Obsidian Therapeutics
Essay
Bruce Booth outlines 2026 biotech predictions including anticipated IPO wave and clinical opportunities ahead.
Chaos is a Ladder: Predictions for 2026
Exit
Portfolio company Akero Therapeutics acquired by Novo Nordisk for $4.7B to expand MASH treatment portfolio.
Akero Therapeutics
New Fund
Closed Opportunity Fund III with $400M to provide growth capital for existing portfolio companies.
Opportunity Fund III
Investment
Co-led Antares Therapeutics' $177M Series A for precision oncology medicines.
Antares Therapeutics
Exit
Portfolio company Sionna went public on NASDAQ, raising $765M for melanoma and cancer immunotherapies.
Sionna